Related Experiment Video

Updated: Mar 2, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

770

Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases

Liqing Hu1, Zeyu Wang1, Rui Yi1

  • 1Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013. China.

Current Medicinal Chemistry
|May 11, 2017
PubMed

Insights

Soluble guanylate cyclase (sGC) shows significant anti-fibrotic potential by blocking transforming growth factor-beta signaling. This highlights sGC as a promising therapeutic target for treating organ fibrosis.

Area of Science:

  • Fibrosis research
  • Molecular biology
  • Pharmacology

Background:

  • Fibrosis is a detrimental condition affecting multiple organs, with limited effective treatments.
  • Soluble guanylate cyclase (sGC) is increasingly recognized for its role in fibrogenesis.
  • Understanding sGC's mechanism in fibrosis is crucial for developing new therapies.

Purpose of the Study:

  • To review the role of soluble guanylate cyclase (sGC) in fibrogenesis.
  • To elucidate the anti-fibrotic mechanisms of sGC stimulation.
  • To highlight sGC as a potential therapeutic target for fibrosis.

Main Methods:

  • Literature review of studies on sGC and fibrosis.
  • Analysis of signaling pathways involved in fibrotic reactions.
  • Discussion of emerging evidence on sGC stimulation and its effects.

Main Results:

  • Activated sGC demonstrates significant anti-fibrotic potential across various organs.
  • sGC stimulation may exert anti-fibrotic effects by inhibiting non-canonical transforming growth factor-beta (TGF-β) signaling.
  • sGC's role extends beyond vascular tone regulation into fibrotic processes.

Conclusions:

  • The soluble guanylate cyclase (sGC) signaling pathway is a key player in fibrogenesis.
  • Targeting sGC represents a promising strategy for developing novel anti-fibrotic treatments.
  • Further research into sGC mechanisms could lead to effective therapies for diverse fibrotic diseases.
Keywords:
Fibrotic diseasesTGF-β signaling pathwayextracellular regulated protein kinasesmechanism of actionsoluble guanylate cyclasesoluble guanylate cyclase modulators

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.0K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
597
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
555
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53